MD Anderson’s Therapeutics Discovery division, Orionis Biosciences launch Project Helios to advance novel small-molecule cancer medicines March 20, 2021 The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division and Orionis Biosciences today announced the launch of Project Helios, a research collaboration designed to unlock new drug development opportunities through genome-scale mapping of drug-target interactions.Combining Orionis’ unique high-throughput drug discovery technologies with the Therapeutics Discovery division’s expertise in small-molecule therapies and translational biology, Project Helios aims to create an unparalleled collection of drug-target interaction data to enable rational drug discovery, optimization and repurposing. The project will focus initially on developing therapies for unmet needs in oncology, with the possibility of expanding to additional therapeutic areas in the future.Read the full article here. Source: MD Anderson Cancer Center Prostate Cancer News
The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division and Orionis Biosciences today announced the launch of Project Helios, a research collaboration designed to unlock new drug development opportunities through genome-scale mapping of drug-target interactions.Combining Orionis’ unique high-throughput drug discovery technologies with the Therapeutics Discovery division’s expertise in small-molecule therapies and translational biology, Project Helios aims to create an unparalleled collection of drug-target interaction data to enable rational drug discovery, optimization and repurposing. The project will focus initially on developing therapies for unmet needs in oncology, with the possibility of expanding to additional therapeutic areas in the future.Read the full article here. Source: MD Anderson Cancer Center
